与法里西马布相关的视网膜血管炎
Mohammad Z Siddiqui1, Alia Durrani1, Bradley T Smith1
1The Retina Institute, St. Louis, MO, USA.
Journal of vitreoretinal diseases
|September 25, 2024
概括
视网膜血管炎 (视网膜血管炎) 是眼睛血管的炎症,可在接受内法里西马布-斯沃亚注射后发生. 用静脉注射类固醇及时治疗有助于视觉恢复.
科学领域:
- 眼科医生 眼科 眼科
- 视网膜血管疾病 视网膜血管疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 静脉内注射是对视网膜疾病的常见治疗方法.
- 法里西马布-斯沃亚是一种新型双特异性抗体,用于新血管与年龄相关的黄斑变性.
研究的目的:
- 为了记录视网膜血管炎的病例后,内法里西马布-svoa的管理.
- 突出这一不良事件的临床表现和管理.
主要方法:
- 案例报告的审查.
- 眼科检查,包括视力敏度和光素血管学.
- 临床管理和结果评估.
主要成果:
- 一名77岁的女性在注射后视力敏度下降.
- 检查发现了视炎,视网膜出血,以及非闭塞性血管炎的血管学证据.
- 静脉注射类固醇治疗导致迅速的视觉恢复和血管炎的解决.
结论:
- 法里西马布-斯沃亚可能与视网膜血管炎有关.
- 早期识别和迅速使用全身性皮质类固醇治疗对于视力恢复至关重要.
相关概念视频
Fibril-associated Collagen
Fibril-associated collagens are a type of collagens present in the extracellular matrix with interrupted triple helices or FACIT (Fibril-associated collagens interrupted triple-helices). FACIT help connect and attach the collagen fibrils with each other as well as with other proteins of the extracellular matrix.
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
Cytomegalovirus Disease
Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...


